ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly outside U.S. realized price impact YoY (%) [Q1–Q3 10-Q & FY 10-K] (%)
Form 10-Q / 10-K MD&A Revenue Growth Decomposition Table
Latest, FY2023
-4.0%
Period ended Dec 31, 2023
Change on a year earlier
+6.0 pts
-10.0% in FY2022
History
7 years
Since FY2017
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Outside U.S. realized price impact YoY (%) [Q1–Q3 10-Q & FY 10-K] (%) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | -4.0% | +6.0 pts | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | -10.0% | -6.0 pts | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | -4.0% | +2.0 pts | Form 10-K FY2021 (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | -6.0% | -5.0 pts | Form 10-K FY2020 (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | -1.0% | +2.0 pts | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | -3.0% | -2.0 pts | Form 10-K FY2018 (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | -1.0% | – | Form 10-K FY2017 (filed 2018-02-20) ↗ |
Cite this data
StockData. (2026). Eli Lilly Outside U.S. realized price impact YoY (%) [Q1–Q3 10-Q & FY 10-K] (%), annual FY2017–FY2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/rev_growth_nonus_price
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.